When Two Worlds Collide – BTG Brings Interventional Oncology And Immunotherapy Together
BTG's range of interventional oncology technologies puts it in an enviable position in R&D initiatives that require a holistic view across cancer and the best-targeted therapies. The UK-listed company will now take this to another level following an agreement with the Society of Interventional Oncology to explore the role of minimally invasive therapies in immuno-oncology.
You may also be interested in...
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
A short comment period for Germany’s future hospital financing bill will be followed by parliamentary debate before it becomes law.
The much-anticipated return to a “normal” NHS service delivery could yet be dashed by a resurgence of the virus.